VanEck Australian Floating Rate ETF vs Personalis Inc. Common Stock — how do they compare? VanEck Australian Floating Rate ETF trades at $50.93 (market cap $11.37B), while Personalis Inc. Common Stock trades at $16.07 (market cap $1.69B). The key difference: VanEck Australian Floating Rate ETF is far larger — about 6.7× Personalis Inc. Common Stock's market cap, and Personalis Inc. Common Stock is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 23 Days and Personalis Inc. Common Stock for 0 Days on average.
| FLOT | PSNL | |
|---|---|---|
Market Cap | $11.37B | $1.69B |
Volume | 2,190,809 | 3,817,236 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $18.38 |
52-Week Low | $50.72 | $5.04 |
Typical Hold Time | 23 Days | 0 Days |
Enterprise Value | — | $1.52B |
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.95 with minimal daily movement (+0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF benefits from floating rate exposure amid Fed tightening, with recent dividends of $0.17-$0.18 paid through October 2026. News highlights concentration risk with 47% bank exposure but positions FLOT as a cash substitute in rising rate environments.
Outlook remains tied to Fed policy, with floating rates offering yield advantage if hikes persist. Key risks include bank sector concentration and rate reversal. Analyst sentiment is cautious due to technical weakness but acknowledges strategic utility for barbell portfolios alongside duration assets.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →Personalis Inc. is a cancer genomics company that provides tumor- and blood-based DNA and RNA sequencing tests, including its NeXT Personal liquid biopsy test for cancer monitoring.
Read more on PSNL →